Characterization of 4 mantle cell lymphoma cell lines: Establishment of an in vitro study model

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 4, 2003, Pages 424-431

  Amin, Hesham M ^a   McDonnell, Timothy J ^a   Medeiros, L Jeffrey ^a   Rassidakis, Georgios Z ^a   Leventaki, Vasiliki ^a   O'Connor, Sean L ^a   Keating, Michael J ^a   Lai, Raymond ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; GREEN FLUORESCENT PROTEIN; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

AGED; APOPTOSIS; ARTICLE; CASE REPORT; CELL CYCLE G1 PHASE; CELL STRUCTURE; CYTOGENETICS; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE TRANSFER; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE; PATHOGENESIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOVIRIDAE; ANTIGENS, SURFACE; APOPTOSIS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, VIRAL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUMINESCENT PROTEINS; LYMPHOMA, MANTLE-CELL; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037391344     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Swerdlow SH, Berger F, Isaacson PI, et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:168-170. World Health Organization Classification of Tumors.
2. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000;64:190-196.
3. Lukas J, Jadayel D, Bartkova J, et al. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene. 1994;9:2159-2167.
4. Oka K, Ohno T, Kita K, et al. PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. Br J Haematol. 1994;86:786-791.
5. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995;87:2715-2723.
6. Lai R, Medeiros LJ. Pathologic diagnosis of mantle cell lymphoma. Clin Lymphoma. 2000;1:197-206.
7. Imoto M, Doki Y, Jiang W, Han EK, Weinstein IB. Effects of cyclin D1 overexpression on G1 progression-related events. Exp Cell Res. 1997;236:173-180.
8. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
9. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-127.
10. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124-2130.
11. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487-3495.
12. Ott MM, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of c),clin D3 and is not related to the proliferative activity. Blood. 1997;90:3154-3159.
13. Greiner TC, Moynihan MJ, Chan WC, et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302-4310.
14. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351-3359.
15. Waf-1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997;89:272-280.
16. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619-626.
17. Drexler HG, Matsuo Y, MacLeod RAF. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000;24:881-911.
18. Drexler HG, Minowada J. History and classification of human leukemialymphoma cell lines. Leuk Lymphoma. 1998;31:305-316.
19. Huang MR, Olsson M, Kallin A, Pettersson U, Totterman TH. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells. Gene Ther. 1997;4:1093-1099.
20. Leon RP, Hedlund T, Meech SJ, et al. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci U S A. 1998;95:13159-13164.
21. Panchal RG, Williams DA, Kitchener PD, et al. Gene transfer: manipulation and monitoring function in cells and tissues. Clin Exp Pharmacol Physiol. 2001; 28:687-691.
22. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102:1323-1326.
23. Qudat R, Ford R, McDonnell TJ, Medeiros LJ, Parker T, Lai R. Comparative studies of two mantle cell lymphoma cell lines, Mino and JeKo-1. Mod Pathol. 2001;14:175A.
24. Daibata M, Kubonishi I, Eguchi T, Yano S, Ohtsuki Y, Miyoshi I. The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B) and Epstein-Barr virus nuclear antigen -negative (SP-53) cell lines with t(11;14)(q13;q32) chromosome abnormality from an intermediate lymphocytic lymphoma. Cancer. 1989; 64:1248-1253.
25. 15CDKN2B genes in certain B cell non-Hodgkin's lymphomas: functional studies in a cell line (Granta 519). Leukemia. 1997;11:64-72.
26. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 1995.
27. Luthra R, Hai S, Pugh WC. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol. 1995;4:4-7.
28. Leibowitz G, Beattie GM, Kafri T, et al. Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes. 1999;48:745-753.
29. Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol. 1997;10:927-932.
30. Ronchetti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood. 1999;93:1330-1337.
31. Janssen JWG, Vaandrager J-W, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1, in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood. 2000;95:2691-2698.
32. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-5622.
33. Bosch F, Campo E, Jares P, et al. Increased expression of PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91:1025-1030.
34. Sola B, Salaün V, Ballet JJ, Troussard X. Transcriptional and post-transcriptional mechanisms induce cyclin-D1 over-expression in B-chronic lymphoproliferative disorder. Int J Cancer. 1999;83:230-234.
35. Decaudin D, Bosq J, Munck JN, et al. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma. 1997; 26:539-550.
36. Bell ND, King JA, Kusyk C, Nelson BP, Sendelbach KM. CD5 negative diffuse mantle cell lymphoma with splenomegaly and bone marrow involvement. South Med J. 1998;91:584-587.
37. Shapiro JL, Miller ML, Pohlman B, Mascha E, Fishleder AJ. CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow: a clinicopathologic study of 40 patients. Am J Clin Pathol. 1999;111:477-487.
38. Nanjangud G, Naresh KN, Nair CN, et al. Translocation (11; 14)(q13;q32) and overexpression of cyclin D1 protein in a CD23-positive low-grade B-cell neoplasm. Cancer Genet Cytogenet. 1998;106:37-43.
39. Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphoma. Am J Clin Pathol. 2001;115:396-403.
40. Rassidakis GZ, Tani E, Svedmyr E, Porwit A, Skoog L. Diagnosis and subclassification of follicle center and mantle cell lymphomas on fine-needle aspirates: a cytologic and immunocytochemical approach based on the Revised European-American Lymphoma (REAL) Classification. Cancer. 1999;87:216-223.
41. Watson P, Wood KM, Lodge A, et al. Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphoma. Histopathology. 2000;36:145-150.
42. Bangerter M, Hildebrand A, Griesshammer M. Immunophenotypic analysis of simultaneous specimens from different sites from the same patient with malignant lymphoma. Cytopathology. 2001;12:168-176.
43. Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRB) in mantle cell lymphomas: correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol. 1996;148:1591-1600.
44. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood. 1998;92:770-777.
45. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 1995;85:2870-2876.
46. Doglioni C, Chiarelli C, Macri E, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185:159-166.
47. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803-1815.
48. Fisher DE. The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis. 2001;6:7-15.
49. Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98: 787-794.
50. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol. 1998;103: 217-219.
51. Peng H, Aiello A, Packham G, Isaacson PG, Pan L. Infrequent bax gene mutations in B-cell lymphomas. J Pathol. 1998;186:378-382.
52. Martini M, D'Alo F, Pierconti F, et al. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. Haematologica. 2000;85:1019-1023.
53. Lai R, Rassidakis GZ, Medeiros LJ, Parker TQ, McDonnel TJ. Activation of STAT3 in mantle cell lymphoma cell lines and tumors. Blood. 2001;98:169b.
54. Meeker TC, Lay LT, Wroblewski JM, Turturro F, Li Z, Seth P. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clin Cancer Res. 1997;3:357-364.
55. Buttgereit P, Weineck S, Ropke G, et al. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther. 2000;7:1145-1155.
56. Turturro F, Heineke HL, Drevyanko TF, Link CJ Jr, Seth P. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Ther. 2000;7:930-933.